Skip to main content
AMRX logo

Amneal Pharmaceuticals, Inc.

AMRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$19.18Today:- (-)1Y +94.05%

As of Oct 16, 2026 close

Market cap
$6.32B
P/E (TTM)
40.14
Forward P/E
19.98
Dividend yield
-
52-week range
$9.56$21.18
Volume (live)
-
Avg. volume (3M)
2.84M

Amneal Pharmaceuticals (AMRX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Amneal Pharmaceuticals generated $339.99M of operating cash flow and spent $114.36M on capital expenditures. That left free cash flow of $225.63M, up 2.5% from $220.11M a year earlier, or 7.5% of revenue.

Amneal Pharmaceuticals Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Amneal Pharmaceuticals, Inc. (AMRX) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income0.07-0.07-0.05-0.250.010.09-0.60-0.200.17
Depreciation & Amortization0.220.240.230.240.230.240.210.140.05
Deferred Income Tax0.000.000.000.000.000.000.37-0.010.00
Stock Based Compensation0.030.030.030.030.030.020.020.170.00
Change in Working Capital-0.200.00-0.05-0.06-0.13-0.06-0.120.010.00
Change in Accounts Receivable-0.12-0.160.13-0.08-0.020.02-0.130.090.04
Change in Inventory-0.09-0.13-0.13-0.10-0.05-0.11-0.02-0.04-0.03
Change in Accounts Payable0.020.29-0.090.11-0.050.00-0.01-0.060.02
Change in Other Working Capital0.060.000.050.120.020.040.040.02-0.02
Other Operating Activities0.060.000.190.110.020.050.120.150.01
Net Cash from Operating Activities0.340.300.350.070.240.380.000.250.23
Investing Activities
Capital Expenditures-0.11-0.07-0.07-0.05-0.05-0.06-0.10-0.10-0.11
Acquisitions0.000.010.00-0.08-0.15-0.250.03-0.320.02
Sales/Maturities of Investments0.00-0.010.00-0.040.000.000.000.000.00
Other Investing Activities-0.04-0.01-0.020.000.000.00-0.010.030.00
Net Cash from Investing Activities-0.11-0.06-0.07-0.17-0.19-0.32-0.02-0.40-0.10
Financing Activities
Debt Repayment-2.81-0.230.02-0.12-0.08-0.04-0.030.540.29
Common Stock Issued0.000.000.000.000.000.000.000.000.00
Common Stock Repurchased0.00-0.010.000.000.000.000.000.000.00
Dividends Paid0.000.000.000.000.000.000.00-0.18-0.38
Other Financing Activities-0.13-0.03-0.24-0.07-0.06-0.01-0.02-0.07-0.01
Net Cash from Financing Activities-0.03-0.21-0.21-0.11-0.140.13-0.050.29-0.10
Summary
Effect of Forex Changes on Cash0.000.000.00-0.010.000.000.000.000.00
Net Change in Cash0.190.020.06-0.22-0.090.19-0.070.140.04
Cash at Beginning of Period0.120.100.040.260.350.150.220.080.04
Cash at End of Period0.310.120.100.040.260.350.150.220.08
Free Cash Flow0.230.220.280.020.190.32-0.100.150.12
Supplemental Disclosures
Interest Paid-0.260.190.140.120.13---
Income Taxes Paid-0.020.000.010.02-0.10---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Amneal Pharmaceuticals Cash Flow

What is Amneal Pharmaceuticals's free cash flow?

Amneal Pharmaceuticals generated free cash flow of $225.63M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $339.99M minus $114.36M of capital expenditures. That was up 2.5% from $220.11M a year earlier. Free cash flow equaled 7.5% of revenue.

How much does Amneal Pharmaceuticals spend on capital expenditures?

Amneal Pharmaceuticals spent $114.36M on capital expenditures in fiscal 2025, compared with $74.99M a year earlier. That equals 33.6% of operating cash flow.

Does Amneal Pharmaceuticals pay dividends or buy back shares?

Amneal Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition